-
1
-
-
70350433797
-
The role of complete response in multiple myeloma
-
Harousseau J.L., Attal M., Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009, 114:3139-3146.
-
(2009)
Blood
, vol.114
, pp. 3139-3146
-
-
Harousseau, J.L.1
Attal, M.2
Avet-Loiseau, H.3
-
2
-
-
67349225687
-
Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete remission and molecular remission in allografted patients with multiple myeloma
-
Kröger N., Badbaran A., Lioznov M., et al. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete remission and molecular remission in allografted patients with multiple myeloma. ExpHematol 2009, 37:791-798.
-
(2009)
ExpHematol
, vol.37
, pp. 791-798
-
-
Kröger, N.1
Badbaran, A.2
Lioznov, M.3
-
3
-
-
33947197286
-
A comparison of allografting with autografting for newly diagnosed myeloma
-
Bruno B., Rotta M., Patriarca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007, 356:1110-1120.
-
(2007)
N Engl J Med
, vol.356
, pp. 1110-1120
-
-
Bruno, B.1
Rotta, M.2
Patriarca, F.3
-
4
-
-
0032895599
-
Molecular and clinical remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma
-
Corradini P., Voena C., Tarella C., et al. Molecular and clinical remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 1999, 17:208-215.
-
(1999)
J Clin Oncol
, vol.17
, pp. 208-215
-
-
Corradini, P.1
Voena, C.2
Tarella, C.3
-
5
-
-
0041438792
-
Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma
-
Corradini P., Cavo M., Lokhorst H., et al. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003, 102:1927-1929.
-
(2003)
Blood
, vol.102
, pp. 1927-1929
-
-
Corradini, P.1
Cavo, M.2
Lokhorst, H.3
-
6
-
-
36349010285
-
Multiple Myeloma (009) study Investigators. Lenalidomide plus dexamethsone for relapsed multiple myeloma in North America
-
Weber D.M., Chen C., Niesvizky R., et al. Multiple Myeloma (009) study Investigators. Lenalidomide plus dexamethsone for relapsed multiple myeloma in North America. N Engl J Med 2007, 357:2133-2142.
-
(2007)
N Engl J Med
, vol.357
, pp. 2133-2142
-
-
Weber, D.M.1
Chen, C.2
Niesvizky, R.3
-
7
-
-
36349023319
-
Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
-
Dimopoulos M., Spencer A., Attal M., et al. Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007, 357:2123-2132.
-
(2007)
N Engl J Med
, vol.357
, pp. 2123-2132
-
-
Dimopoulos, M.1
Spencer, A.2
Attal, M.3
-
8
-
-
76749162262
-
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells
-
Lioznov M., El-Cheikh J., Hoffmann F., et al. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone Marrow Transplant 2010, 45:349-353.
-
(2010)
Bone Marrow Transplant
, vol.45
, pp. 349-353
-
-
Lioznov, M.1
El-Cheikh, J.2
Hoffmann, F.3
-
9
-
-
18244428600
-
Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant
-
Bladé J., Samson D., Reece D., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998, 102:1115-1123.
-
(1998)
Br J Haematol
, vol.102
, pp. 1115-1123
-
-
Bladé, J.1
Samson, D.2
Reece, D.3
-
10
-
-
78649707335
-
Lenalidomide mode of action: linking bench and clinical findings
-
Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev 24 Suppl 1:13-19.
-
Blood Rev
, vol.24
, Issue.SUPPL 1
, pp. 13-19
-
-
Davies, F.1
Baz, R.2
-
11
-
-
77955092382
-
Lenalidomide down regulates the production of interferon-gamma and the expression of inhibitory cytotoxic receptors of human Natural Killer Cells
-
Dauguet N., Fournié J.J., Poupot R., Poupot M. Lenalidomide down regulates the production of interferon-gamma and the expression of inhibitory cytotoxic receptors of human Natural Killer Cells. Cell Immunol 2010, 264:163-170.
-
(2010)
Cell Immunol
, vol.264
, pp. 163-170
-
-
Dauguet, N.1
Fournié, J.J.2
Poupot, R.3
Poupot, M.4
-
12
-
-
28844472902
-
Lenalidomide and thalidomide: mechanisms of action-similarities and differences
-
Anderson K.C. Lenalidomide and thalidomide: mechanisms of action-similarities and differences. Semin Hematol 2005, 42:S3-S8.
-
(2005)
Semin Hematol
, vol.42
-
-
Anderson, K.C.1
-
13
-
-
20444463165
-
Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma
-
Kröger N., Shaw B., Iacobelli S., et al. Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 2005, 129:631-643.
-
(2005)
Br J Haematol
, vol.129
, pp. 631-643
-
-
Kröger, N.1
Shaw, B.2
Iacobelli, S.3
-
14
-
-
60249098439
-
Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenousleukemia
-
Cooley S., Trachtenberg E., Bergemann T.L., et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenousleukemia. Blood 2009, 113:726-732.
-
(2009)
Blood
, vol.113
, pp. 726-732
-
-
Cooley, S.1
Trachtenberg, E.2
Bergemann, T.L.3
-
15
-
-
0037086131
-
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
-
Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
-
(2002)
Science
, vol.295
, pp. 2097-2100
-
-
Ruggeri, L.1
Capanni, M.2
Urbani, E.3
-
16
-
-
80054016181
-
Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma
-
Kröger N., Zabelina T., Berger J., et al. Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia 2011, 25:1657-1661.
-
(2011)
Leukemia
, vol.25
, pp. 1657-1661
-
-
Kröger, N.1
Zabelina, T.2
Berger, J.3
-
17
-
-
80052398586
-
Lenalidomide maintenance following non-myeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 trial
-
Kneppers E., van der Holt B., Kersten M.J., et al. Lenalidomide maintenance following non-myeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 trial. Blood 2011, 118:2413-2419.
-
(2011)
Blood
, vol.118
, pp. 2413-2419
-
-
Kneppers, E.1
van der Holt, B.2
Kersten, M.J.3
-
18
-
-
79551615800
-
The immunostimulatory effect of lenalidomide on NK cell function is profoundly inhibited by concurrent dexamethasone therapy
-
Hsu A.K., Quach H., Tai T., et al. The immunostimulatory effect of lenalidomide on NK cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011, 117:1605-1613.
-
(2011)
Blood
, vol.117
, pp. 1605-1613
-
-
Hsu, A.K.1
Quach, H.2
Tai, T.3
-
19
-
-
77950644007
-
Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function
-
Gandhi A.K., Kang J., Capone L., et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010, 10:155-167.
-
(2010)
Curr Cancer Drug Targets
, vol.10
, pp. 155-167
-
-
Gandhi, A.K.1
Kang, J.2
Capone, L.3
-
20
-
-
80855156719
-
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
-
Zhu Y.X., Braggio E., Shi C.X., et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011, 118:4771-4779.
-
(2011)
Blood
, vol.118
, pp. 4771-4779
-
-
Zhu, Y.X.1
Braggio, E.2
Shi, C.X.3
-
21
-
-
70449719357
-
Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis
-
Chiron D., Pellat-Deceunynck C., Maillasson M., et al. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis. J Immunol 2009, 183:4371-4377.
-
(2009)
J Immunol
, vol.183
, pp. 4371-4377
-
-
Chiron, D.1
Pellat-Deceunynck, C.2
Maillasson, M.3
|